Sedation of Uncooperative Children in Pediatric Dentistry: Propofol, Ketamine, and Midazolam

Preface: The Uncooperative Child in Dental Practice

SECTION 1: MIDAZOLAM

Pharmacology

Routes of Administration & Dosing in Pediatric Dentistry

• Miller's Anesthesia 10e, p. 1732; Roberts and Hedges, p. 3040-3044

Efficacy in Pediatric Dentistry

• Oral midazolam at 0.5 mg/kg is the standard first-line agent for anxiolysis/moderate sedation in pediatric dentistry
• It does NOT consistently render a child motionless; for procedures requiring complete stillness, it is insufficient as a single agent
• The non-IV routes cannot be precisely titrated, meaning depth of sedation is less predictable
• The oral route is first choice in most dental settings because it avoids needles and is better accepted by children
• Combining midazolam with local anesthesia is mandatory for painful procedures since midazolam has no analgesic effect

Advantages

1. Multiple routes available - oral, IN, buccal, IM, IV, rectal - offering flexibility for needle-phobic children
2. Anxiolysis and amnesia - reduces procedural fear and produces anterograde amnesia, which is particularly valuable as it prevents negative memory formation about dental visits
3. Antiemetic - reduces nausea compared to opioid combinations
4. Reversible - flumazenil (0.01 mg/kg IV) is a specific antagonist, improving the safety margin
5. No cardiovascular depression at standard doses; stable hemodynamic profile
6. Well-studied in pediatric dentistry with a large evidence base
7. Anticonvulsant properties beneficial in children with seizure disorders
8. Short duration relative to diazepam, allowing relatively rapid recovery and discharge

Limitations

1. No analgesia - must be combined with local anesthesia for all invasive procedures; inadequate pain control leads to sedation failure
2. Paradoxical reactions - hyperexcitability, agitation, and disinhibition occur in 2-15% of children, especially toddlers and children with developmental disabilities; more common with oral than IV routes
3. Non-IV routes are non-titratable - unpredictable depth of sedation; some children oversedated, others undersedated
4. Incomplete sedation - does not reliably produce complete cooperation in very anxious or younger children when used alone
5. Respiratory depression - enhanced when combined with opioids; close monitoring required
6. Longer onset with oral route (~15-30 min) requiring additional chair/waiting time
7. Bitter taste of oral preparation may cause poor acceptance unless masked with flavoring
8. Tolerance with repeated use; may be less effective in children who have received prior benzodiazepines
9. Paradoxical CNS excitation more likely in children <2 years, making it less reliable in infants

Monitoring Requirements

• Pulse oximetry is mandatory
• Capnography recommended, especially if deep sedation is approached
• Blood pressure and heart rate monitoring
• Flumazenil and resuscitation equipment must be immediately available

SECTION 2: KETAMINE

Pharmacology

Routes of Administration & Dosing in Pediatric Dentistry

• Miller's Anesthesia 10e, p. 1663; Roberts and Hedges, p. 3120-3135

Efficacy in Pediatric Dentistry

Advantages

1. Dissociative sedation preserves airway reflexes - the child maintains laryngeal and pharyngeal reflexes, reducing aspiration risk compared to deep sedation with other agents
2. Analgesia + sedation + amnesia in one drug - particularly advantageous for painful dental procedures (extractions, pulpectomies) where midazolam alone is insufficient
3. IM route enables sedation of violently uncooperative children without requiring prior IV access; onset in 3-5 minutes
4. Cardiovascular stimulation (sympathomimetic effect) increases heart rate and blood pressure, providing a safety buffer in volume-depleted or compromised children
5. Bronchodilator - safe in asthmatic children; reduces bronchospasm risk
6. Multiple routes (IM, IV, oral, IN, rectal) with intranasal becoming increasingly popular for needle-free administration
7. No respiratory depression at standard dissociative doses - maintains spontaneous respiration
8. Short duration with IV route allows procedure-timed sedation
9. Effective even in deeply anxious or combative children where midazolam paradoxically worsens behavior

Limitations

1. Emergence reactions - unpleasant dreams, hallucinations, delirium on recovery; milder in children than adults (uncommon in children) but still possible
2. Hypersalivation and excessive secretions - significant issue in dental procedures as pooled secretions obscure the operative field; requires atropine or glycopyrrolate premedication
3. Nausea and vomiting - occurs in up to 33% of children after IM or oral ketamine; concerning for dental chair setting where suction must be available
4. Nystagmus and random movements - purposeless muscle movements and nystagmus are common; the child appears distressed to parents even though fully analgesic
5. Elevated intracranial pressure - relative contraindication in children with CNS masses, hydrocephalus, or raised ICP (though evidence is weakening)
6. Elevated intraocular pressure - contraindicated in acute globe injuries and glaucoma
7. Laryngospasm risk with stimulation of the posterior pharynx - dental procedures around the pharyngeal area require care; relative contraindication for procedures stimulating the posterior pharynx (endoscopy-like procedures)
8. Prolonged sedation with IM route compared to IV; longer monitoring period required before discharge
9. Cardiovascular contraindications - should be avoided in children with known cardiac disease, hypertension, or thyroid disorders because of sympathomimetic effects
10. Age restriction - avoided in children <3 months due to higher airway complication risk - Roberts and Hedges, p. 3083-3085
11. Oral preparation is unpalatable - bitter taste; poor compliance without flavoring

Special Consideration: Ketamine + Midazolam Combination

Monitoring Requirements

• Pulse oximetry mandatory
• Full resuscitation equipment - atropine for bradycardia/secretions, succinylcholine for laryngospasm
• Quiet, dim-lit recovery area
• No requirement for IV access with IM ketamine, but IV should be obtained if possible

SECTION 3: PROPOFOL

Pharmacology

Routes of Administration & Dosing in Pediatric Dentistry

• Miller's Anesthesia 10e, p. 1648-1651; Roberts and Hedges, p. 3001-3025

Efficacy in Pediatric Dentistry

• Complex or prolonged dental procedures requiring deep sedation
• Children in dedicated dental surgery suites or hospital settings with full anesthetic support
• Cases where rapid titration to the exact required depth is critical
• As part of "ketofol" combination (propofol + ketamine IV) for procedures requiring both analgesia and deep sedation

Advantages

1. Fastest onset (~30 seconds) and most predictable depth of sedation of all three agents
2. Precisely titratable - depth of sedation can be adjusted in real time by changing infusion rate; ideal for procedures with varying stimulation levels
3. Rapid, clean recovery - children return to baseline alertness within minutes of stopping infusion; no "hangover" effect; ideal for outpatient/day-surgery dental settings
4. Antiemetic properties - propofol is the only anesthetic with proven antiemetic effects (reduces postoperative nausea and vomiting); valuable in children prone to PONV
5. Total IV anesthesia (TIVA) capability - can maintain deep sedation or general anesthesia for the full duration of extensive dental treatment
6. No analgesic requirement for smooth sedation - while propofol provides no analgesia, its deep sedation suppresses movement response; combined with local anesthesia it allows fully cooperative conditions
7. Bronchodilation - beneficial in children with reactive airway disease
8. Short duration - rapid discharge readiness reduces chair/unit time

Limitations

1. Exclusively IV - requires IV access, which is the major barrier in uncooperative, needle-phobic children; this is a fundamental limitation compared to midazolam (oral) and ketamine (IM)
2. No analgesia - propofol has zero analgesic activity; must always be combined with local anesthesia; inadequate local anesthesia leads to movement and sedation failure even at deep levels
3. Pain on injection - occurs in 70% or more of patients; severe burning at the injection site, especially with small veins; pretreatment with IV lidocaine (0.5-1 mg/kg) is standard - Miller's Anesthesia 10e, p. 1655
4. Respiratory depression and apnea - after an induction dose, transient apnea occurs frequently; airway obstruction is common and requires jaw thrust or LMA insertion; reported rates of respiratory depression/apnea requiring assisted ventilation: 0% to 3.9% - Roberts and Hedges, p. 3019
5. Hemodynamic depression - transient hypotension in 2.2% to 6.5% due to vasodilation and myocardial depression; less safe in hypovolemic children
6. Propofol Infusion Syndrome (PRIS) - a potentially fatal complication of prolonged propofol infusion in children characterized by lipemia, cardiac dysrhythmias, and refractory metabolic acidosis; described first in 1992 by Parke et al. in 5 ICU children; propofol should NOT be used for long-term sedation in children; infusions should be limited to <24 hours - Miller's Anesthesia 10e, p. 1658
7. Requires skilled operator - safe use of propofol for deep sedation requires operator competency in airway management equivalent to that needed for general anesthesia; not appropriate for routine dental chair use without anesthesiologist support
8. No reversal agent - unlike midazolam (flumazenil) or opioids (naloxone), there is no specific reversal agent for propofol; safety depends entirely on monitoring and supportive care
9. Lipid emulsion vehicle - contains soybean oil and egg lecithin; theoretical caution in children with egg or soy allergy (though clinical evidence for risk is weak)
10. Elevated ICP is NOT a concern (propofol actually reduces ICP), but the drug's lack of analgesic and airway-preservation properties limits its use to settings with full backup
11. Age limitation - not recommended for long-term sedation in any pediatric patient; particular caution in those with mitochondrial disorders who are highly sensitive to PRIS even at low doses - Miller's Anesthesia 10e, p. 1658

Monitoring Requirements (more intensive than midazolam or ketamine)

• Continuous pulse oximetry
• Capnography essential - propofol most commonly requires supplemental oxygen, and when high-flow O2 is used it negates pulse oximetry as an early warning; capnography provides the only reliable early warning of apnea - Roberts and Hedges, p. 2613
• Blood pressure every 3-5 minutes
• ECG monitoring
• IV access mandatory (already required for drug administration)
• Immediate availability of bag-valve-mask, suction, resuscitation drugs
• Skilled airway manager (must be able to perform RSI if needed)

COMPARATIVE SUMMARY TABLE

Clinical Guidelines Summary

• Minimum monitoring: pulse oximetry + trained observer
• Drugs: midazolam oral/IN is the primary agent; ketamine IM is the primary agent for severely uncooperative children
• Propofol for deep sedation requires minimum standards equivalent to those for general anesthesia, including an independent observer trained in pediatric airway management

1. Mildly anxious child (Frankl scale 2-3): Oral midazolam 0.3-0.5 mg/kg + local anesthesia
2. Moderately uncooperative child (Frankl 1-2, unable to accept needle): Intranasal midazolam 0.2-0.3 mg/kg OR intranasal ketamine 7 mg/kg
3. Severely uncooperative / combative child: IM ketamine 2-4 mg/kg ± midazolam premedication (reduces emergence reactions)
4. Complex/prolonged dental treatment (hospital setting): Propofol IV-based TIVA by anesthesiologist; or ketamine + propofol IV combination ("ketofol")
5. Child with airway disease / asthma: Ketamine preferred (bronchodilator); propofol also acceptable
6. Child needing rapid recovery for discharge: Propofol IV (when IV access available) - fastest recovery of all three

Key References

• Roberts and Hedges' Clinical Procedures in Emergency Medicine, p. 2400-3270 (PSA guidelines, propofol, ketamine, midazolam)
• Miller's Anesthesia, 10th Edition, p. 1648-1668 (IV anesthetic agents in children)
• Barash, Cullen & Stoelting's Clinical Anesthesia, 9e, p. 1663
• Rabassa-Blanco J et al. Efficacy of Midazolam in Outpatient Pediatric Dentistry: A Systematic Review. Spec Care Dentist. 2025 (PMID 41121658) - 4,374 children, 28 studies
• Kaur K et al. Intranasal versus sublingual sedation in pediatric dentistry: a systematic review. Eur Arch Paediatr Dent. 2026 (PMID 41513911) - 1,500+ children, 28 studies
• Dubey B et al. Intranasal ketamine vs. midazolam + dexmedetomidine in pediatric dental patients. J Indian Soc Pedod Prev Dent. 2024 (PMID 39250206)